Key Points
- Total revenue declined by 3% year over year to $3.8 billion.
- Viatris reported a net loss of $326 million compared to $264 million earnings last year.
- Guidance for new product revenue was raised to $500 million to $600 million for the year.
Global healthcare company Viatris (VTRS +2.27%)reported second-quarter earnings on Thursday that showed year-over-year declines in several metrics, partially related to several divestitures that occurred in the quarter.
Revenue and net income both fell by single-digit percentages compared to 2023's Q2. Despite the underwhelming performance, Viatris saw growth in new product revenue that encouraged management to increase its guidance for this metric, reflecting solid market uptake of its pharmaceuticals.
The quarter presented a mixed picture with some improvements, but also ongoing financial instability due to strategic reshaping and divestitures.
| Metric | Q2 2024 | Q2 2023 | Change (YOY) |
|---|---|---|---|
| Total revenue | $3.8 billion | $3.9 billion | (3%) |
| U.S. GAAP net income (loss) | ($326 million) | $264 million | N/A |
| Adjusted EBITDA | $1.2 billion | $1.31 billion | (7%)* |
| Adjusted EPS | $0.69 | $0.75 | (8%) |
| Free cash flow | $426 million** | $457 million | (6.8%) |
Source: Viatris. *Adjusted EBITDA would be positive 2% on a divestiture-adjusted operational basis. **Free cash flow excludes transaction costs related to divestitures. YOY = Year over year. GAAP = Generally accepted accounting principles. EBITDA = earnings before interest, taxes, depreciation, and amoritization.
Understanding Viatris
is a global healthcare company providing access to medicines, sustainable operations, and quality healthcare. The company focuses on three therapeutic areas: ophthalmology, gastrointestinal, and dermatology. Recently, it initiated a significant strategic reshaping, including divesting non-core assets and focusing on higher-margin, innovative products.
In recent quarters, Viatris has emphasized capitalizing on emerging strengths within its core business areas. The key to its success lies in leveraging its global operational platform, innovation, and strategic partnerships.
Quarterly Highlights
During Q2 2024, saw notable shifts in its financial and operational metrics. Total revenue of $3.8 billion fell 3% from Q2 2023 while new product revenue reached $210 million, driven by successful launches like Breyna™ and Lisdexamfetamine. This aligns with the increased guidance for new product revenue, reflecting solid market performance.
Despite increased new product sales, Viatris reported a substantial net loss of $326 million. This compares starkly to the prior year's net earnings of $264 million. Adjusted was $1.2 billion, down 7% on a GAAP basis but up 2% when factoring in divestiture-adjusted operations.
Viatris engaged in several strategic divestitures during the quarter. It completed the sale of its over-the-counter (OTC) business to Cooper Consumer Health, its Active Pharmaceutical Ingredients (API) business to Matrix Pharma, and the Women's Healthcare Business to Insud Pharma. These actions are part of Viatris’ broader strategy to focus on core, high-growth therapeutic areas while enhancing financial flexibility.
Revenue from divested segments has been adjusted to show core business growth. Adjusted for divestitures, Viatris’ operational revenue (EBITDA) saw a 2% increase, indicating steady performance in its retained segments. The company’s free cash flow was reported at $426 million, suggesting it might meet its annual target despite strategic costs.
Regionally, Viatris' Greater China operations saw 5% growth despite global constraints, while developed markets showed 1% growth due to new product introductions. However, emerging markets and other regions faced stability challenges due to regulatory changes and market dynamics.
Looking Ahead
Viatris’ management reaffirmed its financial outlook for 2024. Its increased guidance for new product revenue to $500 million to $600 million demonstrates confidence in continued market uptake. The total revenue guidance range remains $14.98 billion to $15.48 billion, aligning with ongoing strategic expectations.
Investors should monitor Viatris’ continued strategic reshaping and integration of new assets. The aim is to realize long-term benefits from recent divestitures and acquisitions. Future quarters will reveal the extent of Viatris’ success in its transformational journey and ability to navigate associated financial challenges.
